3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 115 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmzcW0> MUiybC=> MoTNSG1UVw>? MoH4doVlfWOnczDndo94fGhiaX7obYJqfG:{eTDl[oZm[3Rib3[gRmROSw>? MmDZNlU4OTZ3NkG=
A549  MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLPN41O MnPiNog> NUDzSnFnTE2VTx?= NVTINo8yemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?= M{nTZVI2PzF4NU[x
95D M1;kdmFxd3C2b4Ppd{BCe3OjeR?= MWW1cW0> M{TXXVJp MXTEUXNQ MlXPbY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSq MknVNlU4OTZ3NkG=
A549  MnvBRZBweHSxc3nzJGF{e2G7 M2XqWFVuVQ>? MmDSNog> MXvEUXNQ MXrpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? MYWyOVcyPjV4MR?=
NBL-W-S  M33sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXD[5EydU1? NIXQXJo3cA>? NUDrU5F1\W6qYX7j[ZMhT0GQVD22NUB1d3irY3n0fS=> M1LUPVI2OzJ|MkKy
NBL-W-S  NGTKPI5CeG:ydH;zbZMhSXO|YYm= MnfFNY1O NHnVcGs3cA>? MW\pcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDHRW5VNTZz M2LWbVI2OzJ|MkKy
A2780cp  M2TEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGxcW0> NGX6e3gycA>? MYXpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NVjNbmwzOjV|MkK2PVQ>
A549  NInBZXJHfW6ldHnvckBCe3OjeR?= MknlOY1O NHn5WHgzcA>? MkPYd5VxeHKnc4Pld{BUWENiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhVEN|LVnJ NHnDVlQzPTJ6NU[yPC=>
H157 NGDJeGVHfW6ldHnvckBCe3OjeR?= NXv4dFFIPW2P NV36TGdNOmh? M33YSpN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> NVrhT|dKOjV{OEW2Nlg>
MDR MWjBdI9xfG:|aYOgRZN{[Xl? MYSxNI1O NGmwUHE3cA>? Mn3xd5Rz\W6pdHjlcpMhfGinIIDve4VzKG:oIHHueIlk[W6lZYKg[JJ2\3N? NXO2bod3OjVyMUm3NFE>
HT-29  MVnBdI9xfG:|aYOgRZN{[Xl? MVixcW0> NVfOenpFPDiq Ml6xSG1UVw>? NIXQ[|lmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? MXKyOFg1OjF3OB?=
Microglia  MmLtRZBweHSxc3nzJGF{e2G7 NX;HUlJqPW2P NXKwVGtTOjSq NW\RSXNn\GWlcnXhd4V{KGi7cH;4bYEucW6mdXPl[EBk\WyuIHTlZZRp NHvt[pozPDhzOE[wNS=>
A2780cp MUDBdI9xfG:|aYOgRZN{[Xl? MVqyMlVuVQ>? M3rve|Fp MknD[IRJOk9? Mm\w[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NEfjXIYzPDhzN{m0Oi=>
HepG2 MnrnSpVv[3Srb36gRZN{[Xl? MXy1cW0> MkTKOIg> NUflVJV4cW6lcnXhd4V{KEiOIILlcIVie2V? M33XOlI1PzF|NUi3
A549 MXXBdI9xfG:|aYOgRZN{[Xl? NXvoXHNYPW2P MXe0PIg> M3\CTYRm[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuIHTlZZRpKGGwZDDlfJBz\XO|aX;uJIxmfmWuczDv[kBk[XOyYYPlMVMtKEKnY3zpck0yKGGwZDDMR|MuUUl? NEnZXZkzPDdyNkOwNy=>
U2OS NXnJS2FbSXCxcITvd4l{KEG|c3H5 NVTC[HpDOTCvTR?= NX3GWIlPOjSq M{PXOolvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kB1cGViVULPV{Bk\WyuczDpcoR2[2WmIHL5JGRwgA>? M{PsXFI1PjN7MEGz
Saos-2 MoTPRZBweHSxc3nzJGF{e2G7 MUexNI1O MUiyOIg> NYfweZVOcW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6 NFOzT4YzPDZ|OUCxNy=>
A549 NHW5PXFCeG:ydH;zbZMhSXO|YYm= Mle1NVBuVQ>? MUK0PIg> MWDhZ4NmdGW{YYTld{B1cGVicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgVHRZ MkXiNlQ3OjZ5MkK=
HCT116  MUDBdI9xfG:|aYOgRZN{[Xl? MlLCOY1O M{DMWlI1cA>? NXfBcmNs\W6qYX7j[ZMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JIFxcWenbnnu MnPINlQ3OjZ3MkK=
HGC-27 M2XoUGZ2dmO2aX;uJGF{e2G7 NX7We5JIOTCvTR?= NUGxd5JnOWh? MkLnbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIxwe3NiYomgVmFFODBzIH;yJG1MNTJ{ME[= M4D0b|I1PDF4M{S5
U2OS  NWj5d4RSTnWwY4Tpc44hSXO|YYm= MV:wMlUwOW2P M4jRPVQ5cA>? MVzpcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> NHv2XWQzPDN3OEO0Ni=>
MG-63 MkjWSpVv[3Srb36gRZN{[Xl? NHzHVJkxNjVxMX3N NX\xdGhkPDiq NEC2R4NqdmS3Y3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? NHS0[pEzPDN3OEO0Ni=>
MG-63 M4HlSWFxd3C2b4Ppd{BCe3OjeR?= M1Xmb|AvPS9zbV2= NGf1cnc{Omh? NITFV2VmdmijbnPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygZZBweHSxc3nz M4LzflI1OzV6M{Sy
MG-63 Ml3YRZBweHSxc3nzJGF{e2G7 MoH5NVBuVQ>? M2DwRVEzcA>? NW\aZ4lP\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? NHXVO|AzPDN3OEOwNS=>
NTUB1 NUXWS4J[SXCxcITvd4l{KEG|c3H5 MnK4OY1O NVTyNW1WOS53aB?= NG\xdHVxd3SnboTpZZRmeyClZXzlZ495cWJvaX7keYNm\CCjcH;weI9{cXN? M3TKeFI1OzR7MUe2
T24 M37HZmFxd3C2b4Ppd{BCe3OjeR?= M3L3cVVuVQ>? Mm\nNU42cA>? NIfLbVBxd3SnboTpZZRmeyClZXzlZ495cWJvaX7keYNm\CCjcH;weI9{cXN? Mo\DNlQ{PDlzN{[=
SGC-7901  NVPtdoNDSXCxcITvd4l{KEG|c3H5 MoLxNo1O NVPiU5pmOWh? NGrFTnFqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?= NEf5VFMzPDN{MUO0NC=>
SMMC-7721 M2L5WmFxd3C2b4Ppd{BCe3OjeR?= MoDkNo1O NWLVR|ZtOWh? NGjkOGRqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?= NYTGNnVTOjR|MkGzOFA>
ECSCs  NVPuc3dNSXCxcITvd4l{KEG|c3H5 NFzHfHEyOG2P NULaZZBLPGh? NVPj[mMx\GWlcnXhd4V{KHKjcHHtfYNqdi22cnXheIVlKGGyb4D0c5Nqew>? NHz4VHozPDNzOUGwPS=>
MCF-7  MWnGeY5kfGmxbjDBd5NigQ>? MmDaNVBuVQ>? NILrNJUzPGh? M2PGNolvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDjbIVud3SqZYLhdJkh\HK3Z4O= NULkV|BDOjR|MUW1O|g>
UOK257 NFvsNJlCeG:ydH;zbZMhSXO|YYm= MmT2OY1O M323elNp M1vRU4VvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? MlHvNlQ{ODV4MES=
ACHN-5968 NXPmVVlmSXCxcITvd4l{KEG|c3H5 NInibHU2dU1? MXWzbC=> M130fYVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? MX:yOFMxPTZyNB?=
Huh7 NUPC[lZVSXCxcITvd4l{KEG|c3H5 M{H6R|JuVQ>? MVSxNog> NH\sWnNFVVOR NW[3TpU3cW6qaXLpeJMhSVqGOEC1OU1qdmS3Y3XkJINmdGxiZHXheIg> MYCyOFI6PzNyMB?=
Hep3B M1XkfGFxd3C2b4Ppd{BCe3OjeR?= MXeycW0> MXqxNog> M2PZ[mROW09? Ml\abY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= MXWyOFI6PzNyMB?=
RKO M1Tl[mZ2dmO2aX;uJGF{e2G7 M3e0UlJuVQ>? MmL4NYg> Mo\0SG1UVw>? NH3hbVlmdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> MWWyOFI6OTd5Nx?=
HepG2 E47 MV\GeY5kfGmxbjDBd5NigQ>? M1vEelIvPW2P NIjUNWY1QGh? M4rIcYlv[3KnYYPld{B1cGVidH;4bYNqfHlib3[gRWEtKEKVTzygZY5lKEOFbES= MonhNlQzPzN5M{i=
LoVo  M1e4NWFxd3C2b4Ppd{BCe3OjeR?= MUm1cW0> NIrIdXo1QGh? M{HUU4VvcGGwY3XzJGRESS2rbnT1Z4VlKGGyb4D0c5Nqey5? NHzwU3IzPDJyMUixNi=>
WiDr MV\GeY5kfGmxbjDBd5NigQ>? M4nabVExdU1? NFjlcIYycA>? MUPpcohq[mm2czDQR2JNNWmwZIXj[YQhVEN|IFnJJIV5eHKnc4Ppc44> MUWyOFE6ODR6OR?=
H1299  M4nEdmZ2dmO2aX;uJGF{e2G7 NHnqdlAyOG2P MYi0bC=> NF\XUVBqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NV3qUmdqOjRzN{OyNFg>
H460 NV;CbG01TnWwY4Tpc44hSXO|YYm= NHH2cY0yOG2P M{LzTVRp MX7pcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NFq4XZYzPDF5M{KwPC=>
A549 NXjrT4dxTnWwY4Tpc44hSXO|YYm= MVuxNI1O NWe1Z445PGh? NHTmW45qdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCrcoLh[IlifGmxbh?= NGrMXmYzPDF2MkezOS=>
Hep3B MXnBdI9xfG:|aYOgRZN{[Xl? MoPtOY1O MYWyOIg> Mo\xZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz NX;2No5vOjRyNk[2PVM>
SMMC-7721 M2HKV2Fxd3C2b4Ppd{BCe3OjeR?= NVr3e5ZpPW2P MX2yOIg> NULtPW5E[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ Mm\WNlQxPjZ4OUO=
HO8910 NVq5WmdHSXCxcITvd4l{KEG|c3H5 M2DzcFExdU1? NFrGU2syOmh? NHvReGJmdmijbnPld{BDOTlvaX7keYNm\CCjcH;weI9{cQ>? MV2yN|k5OzZzMB?=
MCF7 MljZSpVv[3Srb36gRZN{[Xl? NGDwelg2dU1? MUWyOIg> NHXvfHFqdmO{ZXHz[ZMhS3WRIHnu[JVk\WRiY3XscEBl\WG2aB?= MorpNlM6PjJ4Mkm=
HONE-1  MmHESpVv[3Srb36gRZN{[Xl? M3HYO|VuVQ>? M{Xqd|Fp M1vad5JmeHKnc4Pld{A3ei2vZXTpZZRm\CCUT2OgdJJw\HWldHnvci=> NXvTZZB2OjN6OUKzOVg>
HeLa MWnGeY5kfGmxbjDBd5NigQ>? MlniNVBuVQ>? M3iyZVJp M3fMWJN2eHC{ZYPz[ZMhVEN|IFnJJIV5eHKnc4Ppd49v Mn\oNlM5PjR5M{i=
HepG2 NYfBe21[TnWwY4Tpc44hSXO|YYm= NE\ibJEyOG2P MmXiNlRp M{DXV4lvcGmkaYTzJJNqXEmJQWKtJIFv\CCKQmPTMYlv\HWlZXSgZZV1d3CqYXf5 NYLlNItoOjN6MUewOFA>
SH-SY5Y M4Pu[WZ2dmO2aX;uJGF{e2G7 M3nSZlFuVQ>? M2DUTFI1cA>? MnLvbY5pcWKrdIOgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IGTPR3A> M4LOSFI{PzR|MUS4
SH-SY5Y NX7QcYdwSXCxcITvd4l{KEG|c3H5 NY\5NHZ{PW2P NXHYb4NIOWh? NI\oelZi[m:uaYPo[ZMh[2WuYYP0do9tKG6ndYLvdJJwfGWldHn2[UBm\m[nY4S= NV\CRXRFOjN4MUmzPVU>
PC12  M4fLeGZ2dmO2aX;uJGF{e2G7 MoO0NVBuVQ>? MlmwNlRp NYraZ3NWf2G2ZYK= NXzvS2ZJyqCrbnjpZol1eyClaIntc5RzgXC|aX6tcIls\SCycn;0[YF{d22jbDDhZ5Rqfmm2eT6= NFrkO4czOzZyM{m3PS=>
OV2008 NH\sbmVCeG:ydH;zbZMhSXO|YYm= M1j1NlVuVQ>? NVOxPIpNOjSq MnrDZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? MoDYNlM2QTJ{OEG=
A2780 M3ry[mFxd3C2b4Ppd{BCe3OjeR?= M2DuclVuVQ>? MVSyOIg> M2X1ZYNwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| MX2yN|U6OjJ6MR?=
Saos-2  MlfWRZBweHSxc3nzJGF{e2G7 NF20cWUydU1? NX;Gfpd6QT[q M4TiOYlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwZIXj[YQh[nliUFPY NE\rOIczOzV4M{G3NS=>
1321N1 NUe4TpNXS3m2b4TvfIlkcXS7IFHzd4F6 NGPGUXo2dU1? NF3Pc5QzPGh? MYLwdo91\WO2czDj[YxtKGGpYXnud5QhWEOQLXnu[JVk\WRidH;4bYNqfHl? NFW1b|gzOzV{NUK2OS=>
SH-SY5Y NVnPZmFYS3m2b4TvfIlkcXS7IFHzd4F6 M{XCRlVuVQ>? NEjp[ZAzPGh? NEDwOm9qdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 NILHWo0zOzV{NUK2OS=>
HT-29  MXPGeY5kfGmxbjDBd5NigQ>? MUWxcW0> MlLUOFgwQT[q NGS0NGhqdmirYnn0d{BCVVCNIHnu[JVk\XNiYYX0c5Bp[WerYzDj[YxtKGSnYYTo M3;EeVI{PTB6Mkey
OR6 MUTGeY5kfGmxbjDBd5NigQ>? M17YdlExdU1? NF7ySpQ4Omh? NIHYV4R{fXCycnXzd4V{KEiFVjDy[ZBtcWOjdHnvckBidmRiZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| Ml3WNlM{QTV6N{W=
Hela  NUjhN4RITnWwY4Tpc44hSXO|YYm= M3jtbVVuVQ>? M2T5OFI1cA>? MmflbY5pcWKrdIOgd5Rien[jdHnvck1qdmS3Y3XkJIF2fG:yaHHnfS=> NIS1PFczOzN7NU[3PS=>
MCF-7  M{GxS2Z2dmO2aX;uJGF{e2G7 Mmn1OY1O NX:3eoRROjSq MYXpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5 NYToT4FVOjN|OUW2O|k>
HUVECs NESySnlHfW6ldHnvckBCe3OjeR?= NEXM[Zk{dU1? M1q3OVI1cA>? MnzLZoxw[2u|IITo[UBxem:2ZXP0bZZmKGWoZnXjeEBw\iC{ZYP2[ZJifHKxbDDifUBqdmirYnn0bY5oKGG3dH;wbIFogQ>? NHznRWIzOzN3OEmyPC=>
T24 MUfGeY5kfGmxbjDBd5NigQ>? NELnfGsyOG2P NUjwO5ZHOWh? M13OVpJm\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIFzDN{Bi\nSncjDiZYlk[WyrbjD0doVifG2nboS= Ml\INlM{PTRyOEC=
U251MG  MXLGeY5kfGmxbjDBd5NigQ>? M2PhWlNuVQ>? M3f4XVFp MVTzeZBxemW|c3XzJGxEOy2LSTDwdo91\WmwIHX4dJJme3Orb36= NYrURYVLOjN|M{i2NVg>
GTL-16  NIftcpRCeG:ydH;zbZMhSXO|YYm= NInvTWc2dU1? MYCyOIg> NYDFT|Y5emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhd{Bkd22yYYLl[EB1dyClZXzsd{B1emWjdHXkJJdqfGhiTVXUJIlvcGmkaYTvdpM> MmnCNlM{OTN2OUC=
T-47D M3LISWZ2dmO2aX;uJGF{e2G7 NVH2N4VjOTCvTR?= NYf1U5lFOmh? Mn;lbY5pcWKrdIOgZZV1d3CqYXf5JJBzd2Onc4OgZY5lKGmwY4LlZZNmeyC{YYDhcZlkcW5iaX7keYNm\CCjcH;weI9{cXN? M3vNN|I{OzByMEK2
PaCa44 NViyWnl6SXCxcITvd4l{KEG|c3H5 NV;wc|NDOi53bV2= MWexbC=> MnjGdoVlfWOnc9Mg[4VvcXCrbj3t[YRq[XSnZDDhdI9xfG:|aYO= NGG1dZMzOzF{NEGxNi=>
MDA-MB231 M1rTe2Z2dmO2aX;uJGF{e2G7 M2[1UFVuVQ>? NXH1d4I{OWh? MX7pcoNz\WG|ZYOgdoV{fmW{YYTyc4wudWWmaXH0[YQh[2G|cHHz[UBi[3SrdnH0bY9vKGGwZDDj[YxtKGSnYYTo MkTDNlMxQDh6NUC=
HeLa MnG4RZBweHSxc3nzJGF{e2G7 MYOxNI1O Moi0Nog> NIS5c3Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZ48ufHKnYYTt[Y51KHerdHigVGVK MUGyN|AxODF|NR?=
SK-HEP-1 NUPFT5ZGSXCxcITvd4l{KEG|c3H5 MmrkNVBuVQ>? NXXqZoEyOWh? NWK0[4tweHKxdHXjeJMh[WejaX7zeEBifXSxcHjh[5kh[W6mIHnu[JVk\XNiYYDvdJRwe2m|IHnuJIJ2\mGuaX6teJJm[XSnZDDj[Yxtew>? NHLmRlUzOjh3OE[0PS=>
HepG2 MVvBdI9xfG:|aYOgRZN{[Xl? M1\zSVNuVQ>? Mo[2OYg> MWjy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGmwZIXj[YQh[nliUVTz MXSyNlg{PjV7NR?=
MCF-7  NELufHRHfW6ldHnvckBCe3OjeR?= M2jwRlJuVQ>? MUOyOIg> MWTpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBVVcLi NVT2VIJGOjR7N{C2O|Y>
MDA-MB-231 M3i0SWZ2dmO2aX;uJGF{e2G7 MX[ycW0> MUCyOIg> NX7qeplRcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> MXuyOFk4ODZ5Nh?=
MCF-7  MYrGeY5kfGmxbjDBd5NigQ>? MkTNNo1O NYq0[I5FPDiq MmDXdJJwdW:2ZYOgWG0ucW6mdXPl[EBk\WyuIHTlZZRp M{O3OVI1QTdyNke2
MDA-MB-231 NFfPNpNHfW6ldHnvckBCe3OjeR?= NIP2R3UzdU1? NXXYSHhoPDiq MVrwdo9ud3SnczDUUU1qdmS3Y3XkJINmdGxiZHXheIg> MWWyOFk4ODZ5Nh?=
PANC-1  M2XuWmFxd3C2b4Ppd{BCe3OjeR?= M2XpWFFuVQ>? MWW0PIg> Ml\ZSG1UVw>? NGT3PWdmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? MoDjNlQ5PDJzNUi=
MDA-MB 231 MXzBdI9xfG:|aYOgRZN{[Xl? MWG1cW0> NWrtdHlXOC53aB?= NV\JZVNzdW:mdXzheIV{KFSxY3;tbY7DtsLiaX7keYNm\CCjcH;weI9{cXN? MoLXNlQ5OzB5OEG=
Microglia  MWnBdI9xfG:|aYOgRZN{[Xl? NYX4SZpxPW2P M{HQU|I1cA>? MXXk[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= NEmycmgzPDhzOE[wNS=>
A2780cp M2XIWGFxd3C2b4Ppd{BCe3OjeR?= NWDX[WV3Oi53bV2= NYnwRoFOOWh? NWS0cWNU\GSKMl:= NWr0dZVM\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? M1HzXFI1QDF5OUS2
HepG2 MYHGeY5kfGmxbjDBd5NigQ>? NX\tUJdJPW2P M3zqZ|Rp MUPpcoNz\WG|ZYOgZ4VtdHWuYYKgcIV3\Wy|IH;mJGhNyqB? M4XuWlI1PzF|NUi3
U2OS NFi0XopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;RNVBuVQ>? NFO5R3QzPGh? Mmi1bY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIHnu[JVk\WRiYomgSI95 M4TRZlI1PjN7MEGz
HCT116 M4LicGFxd3C2b4Ppd{BCe3OjeR?= M1vYRVVuVQ>? NXvtTmxwOjSq MonvSG1UVw>? NGHZbmtmdmijbnPld{BieGmpZX7pck1qdmS3Y3XkJINmdGxiZHXheIg> NHm4W2EzPDZ{NkWyNi=>
MCF-7  MVzBdI9xfG:|aYOgRZN{[Xl? M4TPbFAvOW2P M{LtXFZp MYHlcohidmOnczDzbZJ1cW6xbD3pcoR2[2WmIHHwc5B1d3Orcx?= MmDqNlI4PTF7OEm=
PC-3  Mm\kRZBweHSxc3nzJGF{e2G7 M1S5fFJuVQ>? NITpN2ozcA>? M4Xyb4lv[3KnYYPld{BQWklvaX7keYNm\CClZXzsJIRm[XSq NF63SmgzOjd2NUW4NC=>
U251  MUnBdI9xfG:|aYOgRZN{[Xl? NWXCNWNOPW2P NGDUZlYzPGh? MkLtbY5kemWjc3XzJHMyNWmwZIXj[YQh[2WubDDk[YF1cA>? NGnF[XUzOjV5OUe4PC=>
HeLa  NV\m[nFTSXCxcITvd4l{KEG|c3H5 M2S0OFVuVQ>? Mn7YNlRp MWLpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi= NH3hU5YzOjV2NUGyPC=>
A549 NH:xdZJHfW6ldHnvckBCe3OjeR?= NEPUNIUxNjGvTR?= Mn35NlRp NEPCU2p{fXCycnXzd4V{KFOXMUGyO|QucW6mdXPl[EBk\WyuIHTlZZRp MluwNlI1PjZ7NkC=
pDCs NH\iN5FHfW6ldHnvckBCe3OjeR?= M2[5R|ExdU1? NGHWPYIxNjWq NVO0cYY5yqC{ZXT1Z4V{KHSqZTDpcoR2[3Srb36gc4YhUU[QLd8xJIJ6KHO|Ul7BOFA> M{TRPFIzOzl4NUm5
BGC-823 NYHtcY1NTnWwY4Tpc44hSXO|YYm= NXrLWJRNPW2P NFzNcJQzcA>? Mlf3bY5pcWKrdIOgeIhmKHKjdHWgc4Yh[XW2b4DoZYdq[yClZXzsdy=> M4jZd|IzOzJ{MUWy
U937 M2HMc2Z2dmO2aX;uJGF{e2G7 NXnPfFZ3Om2P MoHiNVJp NYG3VIJK\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?= MXmyNlE2PTF3MB?=
Marc-145 M1rvSmZ2dmO2aX;uJGF{e2G7 MUW1cW0> MV:xNk8zPC9|Nni= M37QXJJm\HWlZYOgeIhmKFCUUmPWJJRqfGW{czDhcoQhfGinIIDyc5RmcW5iZYjwdoV{e2mxbh?= NULxfI1uOjJzMUm5NFA>
HBx  NXzaUIpOSXCxcITvd4l{KEG|c3H5 NWXQTY5qOTCvTR?= NYX3dHZuPDiq MUjEUXNQ MoLTbY5kemWjc3XzJINmdGxiZHXheIg> MmfmNlIxOjByN{i=
MCF-7 MUHGeY5kfGmxbjDBd5NigQ>? MnrINVBuVQ>? MWm0PIg> NHO4bYtjdG:la4OgZZV1d3CqYXf5JIlv\HWlZXSgZpkh[m:{dHX6c41q[g>? MVKyNVk{OTl|Nx?=
RMPI8226  NVKwcJBjTnWwY4Tpc44hSXO|YYm= Ml7xOY1O M1rRTlFp NUDLOI5We3WycILld5NmeyC2aHWgcIV3\Wxib3[gZZV1d3CqYXf5JJVv\GW{IH71eJJq\W62IHTldIxmfGmxbh?= NELnemMzOTlzNU[yNC=>
PC12/TetOn M1rIOWZ2dmO2aX;uJGF{e2G7 MnLlNE4yNzGvTR?= Mof3NVhp NV[wXIt3dGWjZIOgeI8h|rFvc4nuLHdVMSCjY3P1cZVt[XSrb36sJJRwgGmlaYT5MEBidmRib3zp[49u\XJiZn;ycYF1cW:wwrC= MYmyNVkxPjZ3OR?=
HeLa  NIL6NFFEgXSxdH;4bYNqfHliQYPzZZk> MV:ycW0> Mn3SNlRp M2LmU4lvcGmkaYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKHOrbHnibY5qdiC2bzDI[WxiKGOnbHzzMi=> M2rQN|IyQDd3M{i1
Jurkat NXPaSVR1TnWwY4Tpc44hSXO|YYm= MV2xNI1O MVOxbC=> MX3k[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| MljQNlE5PjRyM{e=
K562 NUnSZW4zTnWwY4Tpc44hSXO|YYm= NYC3W|FqOTCvTR?= NWftSXRXOWh? MXXk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| MnKzNlE5PjRyM{e=
Nara-H MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LIOlVuVQ>? NYTMfFBKPDiq NV;Rd4JP\W6qYX7j[ZMhfGWvc3nyc4xqdXW|bXXkbYF1\WRic4XwdJJme3Orb36gc4YhVmG{YT3IJINmdGxicILvcIln\XKjdHnvci=> MUSyNVgxPTB|Mx?=
HUVECs NH;HVJdHfW6ldHnvckBCe3OjeR?= MXmxNI1O NGTC[3IxNjWq NVzaeolS\GWlcnXhd4V{KHSqZTDBS2UuSlODaX7keYNm\CCjdYTvdIhi\3libHX2[S=> M{DnV|IyPDZ6NUmy
HepG2 NXGweHFxSXCxcITvd4l{KEG|c3H5 MYSycW0> MV2xbC=> NVjZdpRp\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDDk[YF1cA>? NVzhPHpMOjF2NUO2PVE>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
- Collapse

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
- Collapse
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID